US6150508A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
Assignee: NORTHWEST BIOTHERAPEUTICALS Inc
•
Filing: 1998-03-18
•
Granted: 2000-11-21
•
Expires: 2018-03-18
Abstract
Abstract The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.
Inventors
- 👤 Gerald P. Murphy
- 👤 Alton L. Boynton
- 👤 Eric H. Holmes
- 👤 William Thomas Tino
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 09:43
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; A; A61; A61P; A61P13/00; A61P13/08; A61P35/00; C07K16/00; C07K16/18; C07K16/28; A61K; A61K38/00; C07K2317/00; C07K2317/30; C07K2317/34; C12; C12N; C12N2799/00; C12N2799/02; C12N2799/021; C12N2799/026; Y; Y10; Y10S; Y10S435/00; Y10S435/81
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
65 words
A hybridoma cell line selected from the group consisting of 3F5.4G6 having ATCC accession number HB12060, 3D7-1.I. having ATCC accession number HB12309, 4E10-1.14 having ATCC accession number HB12310, 3E11 (ATCC HB12488), 4D8 (ATCC HB12487), 3E6 (ATCC HB12486), 3C9 (ATCC HB12484), 2C7 (ATCC HB12490), 1G3 (ATCC HB12489), 3C4 (ATCC HB12494), 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), 1G9 (ATCC HB12495), 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485).
Claim 2
Dependent Claim
65 words
A hybridoma cell line selected from the group consisting of 3F5.4G6 having ATCC accession number HB12060, 3D7-1.I. having ATCC accession number HB12309, 4E10-1.14 having ATCC accession number HB12310, 3E11 (ATCC HB12488), 4D8 (ATCC HB12487), 3E6 (ATCC HB12486), 3C9 (ATCC HB12484), 2C7 (ATCC HB12490), 1G3 (ATCC HB12489), 3C4 (ATCC HB12494), 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), 1G9 (ATCC HB12495), 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485).
Claim 3
Dependent Claim
82 words
A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG. 1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, which in said second antibody is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB12492).
Claim 4
Dependent Claim
82 words
A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG. 1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, which in said second antibody is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB12492).
Claim 5
Dependent Claim
23 words
A kit for diagnosis, prognosis or monitoring prostate cancer, comprising the monoclonal antibody according to claim 2 or an antigen binding fragment thereof.
Claim 6
Dependent Claim
25 words
The kit according to claim 3 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.
Claim 7
Dependent Claim
30 words
A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060) 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB12492).
Claim 8
Dependent Claim
30 words
A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060) 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB12492).
Claim 9
Dependent Claim
28 words
The monoclonal antibody of claim 5, which is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB12492).
Claim 10
Dependent Claim
84 words
A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostatic specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG. 1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).
Claim 11
Dependent Claim
84 words
A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostatic specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG. 1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).
Claim 12
Dependent Claim
23 words
A kit for diagnosis, prognosis or monitoring prostate cancer, comprising the monoclonal antibody according to claim 7 or an antigen binding fragment thereof.
Claim 13
Dependent Claim
25 words
The kit according to claim 8 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.
Claim 14
Dependent Claim
33 words
A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310, 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).
Claim 15
Dependent Claim
33 words
A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310, 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).
Claim 16
Dependent Claim
31 words
The monoclonal antibody of claim 10, which is produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).
Claim 17
Dependent Claim
81 words
A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG. 1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), and 1G9 (ATCC HB12495).
Claim 18
Dependent Claim
81 words
A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG. 1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), and 1G9 (ATCC HB12495).
Claim 19
Dependent Claim
23 words
A kit for diagnosis, prognosis or monitoring prostatic cancer, comprising the monoclonal antibody according to claim 11, or an antigen binding fragment thereof.
Claim 20
Dependent Claim
25 words
The kit according to claim 13 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.
Claim 21
Dependent Claim
30 words
A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), and 1G9 (ATCC HB12495).
Claim 22
Dependent Claim
30 words
A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB12493), and 1G9 (ATCC HB12495).
Claim 23
Dependent Claim
27 words
The monoclonal antibody of claim 15, which is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB12493),and 1G9 (ATCC HB12495).
References Cited (Backward Citations)
US5162504A
Cited
US5489525A
Cited
WO1994009820A1
Cited
US5538866A
Cited
WO1996039185A1
Cited
WO1998003873A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-11-21 | 2004-05-22 | 2004-11-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-11-21 | 2008-05-22 | 2008-11-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-11-21 | 2012-05-22 | 2012-11-21 | $7700.00 | Window Closed / Lapsed |